These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2317160)

  • 41. Degradation of cross-linked fibrin by human leukocyte proteases.
    Francis CW; Marder VJ
    J Lab Clin Med; 1986 Apr; 107(4):342-52. PubMed ID: 3514776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas.
    Valenzuela R; Shainoff JR; DiBello PM; Urbanic DA; Anderson JM; Matsueda GR; Kudryk BJ
    Am J Pathol; 1992 Oct; 141(4):861-80. PubMed ID: 1415480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The structure of soluble fibrin complexes and fibrin degradation products after Echis carinatus bite.
    Edgar W; Warrell MJ; Warrell DA; Prentice CR
    Br J Haematol; 1980 Mar; 44(3):471-81. PubMed ID: 7378311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Isolation of fibrinogen-fibrin related antigen from human plasma by immuno-affinity chromatography: its characterization in normal subjects and in defibrinating patients with abruptio placentae and disseminated cancer.
    Merskey C; Johnson AJ; Harris JU; Wang MT; Swain S
    Br J Haematol; 1980 Apr; 44(4):655-70. PubMed ID: 7378321
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fibrin and fibrinogen proteolysis products: comparison between gel filtration and SDS polyacrylamide electrophoresis analysis.
    Alkjaersig N; Davies A; Fletcher A
    Thromb Haemost; 1977 Aug; 38(2):524-5. PubMed ID: 145666
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A diazophenylthio-ether-IgG probe for analysing fibrin- and fibrinogen-related antigens.
    Kruskal JB; Maeder DL; Purves LR; Franks JJ; Kirsch RE
    S Afr Med J; 1987 Feb; 71(4):211-7. PubMed ID: 3824087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generation of forms of fragment E with differing thrombin-binding properties during digestion of fibrinogen by plasmin.
    Goodwin CA; Kakkar VV; Scully MF
    Biochem J; 1992 Feb; 281 ( Pt 3)(Pt 3):613-8. PubMed ID: 1531588
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct evidence for systemic fibrinogenolysis in a patient with metastatic prostatic cancer.
    Okajima K; Kohno I; Tsuruta J; Okabe H; Takatsuki K; Binder BR
    Thromb Res; 1992 Jun; 66(6):717-27. PubMed ID: 1519230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fibrinogen A alpha and gamma-chain dimers as potential differential indicators of atherosclerotic and thrombotic vascular disease.
    Shainoff JR; Valenzuela R; Urbanic DA; DiBello PM; Lucas FV; Graor R
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):499-503. PubMed ID: 1983461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fibrin formation and degradation in patients with arteriosclerotic disease.
    Herren T; Stricker H; Haeberli A; Do DD; Straub PW
    Circulation; 1994 Dec; 90(6):2679-86. PubMed ID: 7994808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline.
    Nossel HL; Wasser J; Kaplan KL; LaGamma KS; Yudelman I; Canfield RE
    J Clin Invest; 1979 Nov; 64(5):1371-8. PubMed ID: 500818
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative determination of fibrin and fibrinogen in biological material.
    Haeberli A; Straub PW
    J Lab Clin Med; 1980 Aug; 96(2):258-66. PubMed ID: 6447180
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fibrinogen, fibrin turnover, endothelial products and vascular surgery.
    Woodburn KR; Lowe GD
    Br J Surg; 1997 Aug; 84(8):1059-64. PubMed ID: 9278641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fibronectin distribution in human aortic intima and atherosclerotic lesions: concentration of soluble and collagenase-releasable fractions.
    Smith EB; Ashall C
    Biochim Biophys Acta; 1986 Jan; 880(1):10-5. PubMed ID: 3002486
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
    Smith EB
    Clin Haematol; 1986 May; 15(2):355-70. PubMed ID: 3524931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Soluble fibrin species in arterial thrombi.
    Sandbaek G; Bjørnsen S; Sobel JH; Nieuwenhuizen W; Matsueda G; Brosstad F
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):1-5. PubMed ID: 10691094
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of fibrinopeptide cleavage on the plasmic degradation pathways of human cross-linked fibrin.
    Olexa SA; Budzynski AZ
    Biochemistry; 1980 Feb; 19(4):647-51. PubMed ID: 6444516
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
    Mombelli G; Monotti R; Haeberli A; Straub PW
    Thromb Haemost; 1987 Aug; 58(2):758-63. PubMed ID: 3672428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin.
    Harpel PC; Gordon BR; Parker TS
    Proc Natl Acad Sci U S A; 1989 May; 86(10):3847-51. PubMed ID: 2524834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
    Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
    Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.